- List signs and symptoms of indolent and aggressive NHL subtypes & CLL
- Explain diagnosis and treatment planning for indolent and aggressive NHL subtypes & CLL
- Identify current and emerging treatment options for patients with indolent or aggressive NHL subtypes or CLL
- Describe the importance of clinical trials in improving patient outcomes
- Discuss side effects management and other survivorship issues for patients
- Explain the importance of patient-provider communications
- Review all contents of this activity
- Complete and submit the learning assessment and evaluation form
- Score at least 70% on the learning assessment
RMEI Privacy Statement
Assistance for people with disabilities, grievances, questions or for more information on LLS programs, please call an LLS Information Specialist toll free at (800) 955-4572.